HAE

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Haemonetics Corp revenue for the last quarter amounts to 327.32M USD, decreased -5.27 % YoY.

Haemonetics Corp. EPS for the last quarter amounts to 0.81 USD, increased 22.73 % YoY.

Haemonetics Corp (HAE) has 3023 emplpoyees as of January 07 2026.

Today HAE has the market capitalization of 3.89B USD.